GH Research PLC (GHRS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
GH Research PLC (GHRS) surged +3.82% to $21.50, trading at 49% of its 52-week range ($12.04 – $31.44). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
GH Research has delivered a powerful share price run over the past few years, yet the recent pullback puts fresh attention on a basic question. Is the current US$18.15 price still in line with what its balance sheet and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GHRS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GHRS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, GH Research PLC (GHRS) ranks #227 by composite RQD confidence (58/100, grade D+) and #307 by equity capitalization ($1.47B). Within this direct 5-issuer industry benchmark cohort, GHRS leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ETON currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with GHRS at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GHRS
ACTIVE
GH Research PLC | D+ | 58/100 | — | — | — | +3.82% | $1.47B | Benchmark Subject |
| TYRA Tyra Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -1.24% | $1.48B | /tyra-vs-ghrs → |
| PCRX Pacira BioSciences Inc. | D+ | 54/100 | — | 79.4% | 1.7% | 0.00% | $1.45B | /pcrx-vs-ghrs → |
| ANAB AnaptysBio Inc. | C- | 61/100 | — | — | 85.0% | -3.68% | $1.44B | /anab-vs-ghrs → |
| ETON Eton Pharmaceuticals Inc. | C | 62/100 | — | 53.5% | -0.9% | +3.61% | $1.53B | /eton-vs-ghrs → |
GH Research PLC (GHRS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.47B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, GH Research PLC (NASDAQ: GHRS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $21.50 (+3.82% 1D, market cap $1.47B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GHRS ranks #227 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GHRS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TYRA (Tyra Biosciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.48B) and PCRX (Pacira BioSciences Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B). Among the 5-stock peer group, GHRS leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
For GH Research PLC (GHRS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #227 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
GHRS last traded at $21.50 (+3.82% on volume of 345,242 shares), positioning the stock -10.64% below its 50-day simple moving average ($24.06) and -0.23% below its 200-day simple moving average ($21.55). Across its 52-week range of $12.04 to $31.44, GHRS sits at the 48.8% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.4% ($18.83 to $24.17).
Why GHRS Stock surged +3.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.